CMS GUARD Model 2026: A Complete Guide for Pharma and Biotech
December 2025 marked a defining moment in U.S. drug pricing and Medicare reimbursement policy. Alongside
December 2025 marked a defining moment in U.S. drug pricing and Medicare reimbursement policy. Alongside
December 2025 marked a pivotal moment in U.S. drug pricing policy. The Global Benchmark for
Most Favoured Nation (MFN) pricing policies are increasingly shaping global pharmaceutical launch, pricing, and access
What began as “Most Favored Nation” (MFN) concepts has now materialized into concrete policy mechanisms.
The EU Health Technology Assessment Regulation (HTAR) represents one of the most significant shifts in
In 2023, U.S. retail prescription drug market value grew 11.4% to $449.7B, about 9% of